Assessment of Candidate Protein Expression in Breast Cancer Specimens
1 other identifier
observational
460
1 country
1
Brief Summary
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 9, 2009
CompletedFirst Posted
Study publicly available on registry
June 11, 2009
CompletedStudy Start
First participant enrolled
January 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 23, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 23, 2021
CompletedAugust 1, 2022
July 1, 2022
10.7 years
June 9, 2009
July 29, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Differential expression of candidate genes between normal and cancer breast tissues
Approximately 5 slides of each tumor will be collected to provide sufficient samples for replicate staining, if necessary, as well as a staining for a positive control
non-applicable
Interventions
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Eligibility Criteria
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
You may qualify if:
- DISEASE CHARACTERISTICS:
- Diagnosis of breast cancer
- Tissue samples available
- Samples are selected based on presence or absence of tumor receptors, (i.e.; estrogen, progesterone, and HER2 receptors) and grouped into following 4 categories:
- Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive/HER2-negative
- ER-positive/PR-positive/ HER2-positive by FISH
- ER-negative/PR-negative/HER2-positive
- ER-negative/PR-negative/HER2-negative(triple negative or basal-type cancers)
- PATIENT CHARACTERISTICS:
- Menopausal status not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065, United States
Related Links
Biospecimen
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stefanie Avril, MD
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 9, 2009
First Posted
June 11, 2009
Study Start
January 1, 2011
Primary Completion
September 23, 2021
Study Completion
September 23, 2021
Last Updated
August 1, 2022
Record last verified: 2022-07